vs
Side-by-side financial comparison of TECK RESOURCES LTD (TECK) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.
TECK RESOURCES LTD is the larger business by last-quarter revenue ($6.3B vs $3.0B, roughly 2.1× Vertex Pharmaceuticals).
Teck Resources Limited is a diversified natural resources company headquartered in Vancouver, British Columbia, that is engaged in mining and mineral development, including coal for the steelmaking industry, copper, zinc, and energy. Secondary products include lead, silver, gold, molybdenum, germanium, indium and cadmium. Teck Resources was formed from the amalgamation of Teck and Cominco in 2001.
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
TECK vs VRTX — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $6.3B | $3.0B |
| Net Profit | — | $1.0B |
| Gross Margin | 17.0% | 86.8% |
| Operating Margin | -3.0% | 38.1% |
| Net Margin | — | 34.5% |
| Revenue YoY | — | 7.8% |
| Net Profit YoY | — | 59.6% |
| EPS (diluted) | — | $4.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $3.0B | ||
| Q4 25 | — | $3.2B | ||
| Q3 25 | $6.3B | $3.1B | ||
| Q2 25 | $3.4B | $3.0B | ||
| Q1 25 | $1.6B | $2.8B | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | $4.6B | $2.8B | ||
| Q2 24 | $7.3B | $2.6B |
| Q1 26 | — | $1.0B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $646.3M | ||
| Q4 24 | — | $913.0M | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $-3.6B |
| Q1 26 | — | 86.8% | ||
| Q4 25 | — | 85.4% | ||
| Q3 25 | 17.0% | 86.5% | ||
| Q2 25 | 17.2% | 86.3% | ||
| Q1 25 | 10.4% | 86.9% | ||
| Q4 24 | — | 85.5% | ||
| Q3 24 | 20.7% | 85.8% | ||
| Q2 24 | 42.1% | 85.9% |
| Q1 26 | — | 38.1% | ||
| Q4 25 | — | 37.8% | ||
| Q3 25 | -3.0% | 38.6% | ||
| Q2 25 | -3.8% | 38.8% | ||
| Q1 25 | -2.2% | 22.7% | ||
| Q4 24 | — | 35.2% | ||
| Q3 24 | — | 40.3% | ||
| Q2 24 | 39.8% | -132.9% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | — | 37.3% | ||
| Q3 25 | — | 35.2% | ||
| Q2 25 | — | 34.8% | ||
| Q1 25 | — | 23.3% | ||
| Q4 24 | — | 31.4% | ||
| Q3 24 | — | 37.7% | ||
| Q2 24 | — | -135.8% |
| Q1 26 | — | $4.02 | ||
| Q4 25 | — | $4.64 | ||
| Q3 25 | — | $4.20 | ||
| Q2 25 | — | $3.99 | ||
| Q1 25 | — | $2.49 | ||
| Q4 24 | — | $3.62 | ||
| Q3 24 | — | $4.01 | ||
| Q2 24 | — | $-13.92 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $19.4B |
| Total Assets | — | $26.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $6.6B | ||
| Q3 25 | — | $6.3B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.2B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.5B | ||
| Q2 24 | — | $5.8B |
| Q1 26 | — | $19.4B | ||
| Q4 25 | — | $18.7B | ||
| Q3 25 | — | $17.3B | ||
| Q2 25 | — | $17.2B | ||
| Q1 25 | — | $16.5B | ||
| Q4 24 | — | $16.4B | ||
| Q3 24 | — | $15.6B | ||
| Q2 24 | — | $14.8B |
| Q1 26 | — | $26.5B | ||
| Q4 25 | — | $25.6B | ||
| Q3 25 | — | $24.9B | ||
| Q2 25 | — | $24.0B | ||
| Q1 25 | — | $22.9B | ||
| Q4 24 | — | $22.5B | ||
| Q3 24 | — | $22.2B | ||
| Q2 24 | — | $20.1B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECK
Segment breakdown not available.
VRTX
| TRIKAFTA/KAFTRIO | $2.4B | 79% |
| ALYFTREK | $424.4M | 14% |
| Other | $135.9M | 5% |
| CASGEVY | $42.9M | 1% |
| Vertex recorded | $29.0M | 1% |
